Meeting
2013 ASCO Annual Meeting
Clinical outcomes after intensive VDT-PACE therapy for relapsed multiple myeloma.
Authors
Preet Paul Singh
Mayo Clinic, Rochester, MN
Preet Paul Singh , Wilson I. Gonsalves , Vinay Gupta , Francis Buadi , Martha Lacy , Angela Dispenzieri , Morie Gertz , Suzanne R. Hayman , David Dingli , Stephen J. Russell , John Anthony Lust , Steven R. Zeldenrust , Prashant Kapoor , Arleigh Robertson McCurdy , S. Vincent Rajkumar , Shaji Kumar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8600)
DOI
10.1200/jco.2013.31.15_suppl.8600
Abstract #
8600
Poster Bd #
55E
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).
First Author: James R. Berenson
Poster
2023 ASCO Quality Care Symposium
Acute oncology care at home for post-chemotherapy monitoring in patients with multiple myeloma.
First Author: Melanie Wain Kier
Poster
2020 ASCO Virtual Scientific Program
Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.
First Author: Stefan Knop
Poster
2014 ASCO Annual Meeting
Optimizing induction and pretransplant consolidation for myeloma: Results of Myeloma XI, a phase III trial comparing different IMiDs.
First Author: Charlotte Pawlyn